How Do Peptides Work? Mechanisms, Receptors and Signalling (UK Researcher’s Guide 2026)

Peptides — short chains of amino acids linked by peptide bonds — achieve their biological effects through a remarkably diverse set of mechanisms. Understanding how research peptides work at the molecular level is foundational to designing valid studies, interpreting results, and selecting the right compound for a given research question. This guide covers the core mechanisms through which research peptides interact with biological systems.

What Is a Peptide?

Proteins and peptides are both chains of amino acids connected by peptide bonds — the condensation bond between the carboxyl group of one amino acid and the amino group of the next. The distinction between peptides and proteins is primarily one of size: peptides typically contain fewer than 50 amino acids, while proteins (polypeptides) are longer chains that fold into defined three-dimensional structures.

Research peptides span a wide size range: the tetrapeptide Epitalon has just 4 amino acids, the nonapeptide DSIP has 9, BPC-157 has 15, Thymosin Alpha-1 has 28, and Sermorelin — at 29 amino acids — approaches the protein boundary. Their relatively small size compared to full proteins means they are synthesised chemically (via solid-phase peptide synthesis) rather than biosynthetically, which allows precise control over sequence and modification.

Receptor-Mediated Mechanisms

The majority of research peptides achieve their effects by binding to specific cell-surface receptors, triggering downstream signalling cascades. The main receptor classes relevant to research peptides:

G-protein coupled receptors (GPCRs): The largest receptor superfamily in the human genome, GPCRs respond to peptide ligands by activating intracellular G-proteins that modulate second messenger systems — cAMP, IP3, DAG, and calcium signalling. GH secretagogues (Ipamorelin, GHRP-6) act through GHS-R1a, a GPCR. PT-141 acts through melanocortin receptors MC3R and MC4R, both GPCRs. DSIP is hypothesised to interact with opioid receptors (also GPCRs).

Receptor tyrosine kinases (RTKs): Growth factor receptors including IGF-1R and EGFR are RTKs — binding of their peptide ligands triggers receptor dimerisation and autophosphorylation, activating PI3K/Akt/mTOR and MAPK/ERK signalling cascades. IGF-1 LR3 acts through IGF-1R; GHK-Cu transactivates EGFR.

Cytokine receptors: Many immunomodulatory peptides (Thymosin Alpha-1, LL-37) act through cytokine receptor complexes that activate JAK/STAT signalling pathways, modulating gene expression programmes for immune cell function.

Nuclear receptors: Some peptide-induced signalling ultimately affects nuclear receptor activity — for example, GHK-Cu’s effects on gene expression involve modulation of transcription factor activity including NF-κB and AP-1.

Pattern recognition receptors: LL-37 interacts with formyl peptide receptor 2 (FPR2/FPRL1) — a G-protein coupled pattern recognition receptor — and also modulates TLR signalling indirectly through LPS neutralisation.

Intracellular Mechanisms

Some peptides act at intracellular rather than cell-surface targets:

Actin-binding peptides: TB-500 (Thymosin Beta-4 analogue) binds G-actin monomers directly inside cells, sequestering them and regulating the G-actin/F-actin equilibrium — the foundation of cytoskeletal dynamics and cell motility. This is a direct intracellular mechanism without receptor intermediary.

Gene regulation: GHK-Cu demonstrates the capacity to modulate gene expression at a global scale — over 4,000 genes affected in fibroblast cultures. While the initial interaction is with surface receptors (EGFR transactivation), the downstream effects involve epigenetic modulation and transcription factor activation that produces broad gene expression changes.

Neurotrophic Factor Upregulation

Several nootropic and neuroprotective peptides achieve their cognitive and neural effects primarily by upregulating endogenous neurotrophic factors — the brain’s own growth and maintenance proteins:

BDNF (Brain-Derived Neurotrophic Factor) is upregulated by Selank, Semax, and exercise. BDNF binds TrkB receptors on neurons, activating PI3K/Akt survival signalling and MAPK/ERK plasticity signalling. It is the primary molecular mediator of long-term potentiation (LTP) — the synaptic mechanism underlying memory formation. BDNF also promotes neurogenesis in the hippocampus.

VEGF (Vascular Endothelial Growth Factor) is upregulated by Semax, BPC-157, and GHK-Cu. VEGF drives angiogenesis (new blood vessel formation) through VEGFR2 on endothelial cells, improving vascular supply to healing tissue or neural tissue under ischaemic stress.

NGF (Nerve Growth Factor) is upregulated by Semax. NGF binds TrkA receptors on neurons, promoting neuronal survival, axonal growth, and synaptic maintenance — particularly in cholinergic neurons of the basal forebrain, which are among the first to degenerate in Alzheimer’s disease.

HPA Axis Modulation

Several research peptides modulate the hypothalamic-pituitary-adrenal (HPA) axis — the body’s primary stress response system. DSIP reduces ACTH and cortisol levels in stressed animals. Selank modulates corticotropin-releasing factor (CRF) signalling. Epitalon normalises cortisol diurnal rhythms disrupted in ageing. This HPA modulation has cascading effects on metabolism, immune function, cognitive performance, and sleep — making it a relevant mechanism for a wide range of research applications.

Angiogenesis: The Vascular Repair Pathway

Multiple research peptides promote angiogenesis — the formation of new blood vessels — through VEGF upregulation and NO signalling. BPC-157’s eNOS activation produces NO in endothelial cells, which drives vasodilation and new capillary formation at injury sites. GHK-Cu stimulates VEGF in fibroblasts and endothelial cells. TB-500 promotes endothelial cell migration (the first step in angiogenesis) through its actin cytoskeletal mechanism.

Angiogenesis is a rate-limiting step in virtually all tissue repair processes — without adequate vascular supply, healing tissue cannot receive the oxygen and nutrients required for cell division and matrix synthesis. Peptides that promote angiogenesis therefore have broad relevance to repair biology across tissue types.

The Nitric Oxide (NO) System

Nitric oxide is produced by three isoforms of nitric oxide synthase: eNOS (endothelial, cardiovascular protective), nNOS (neuronal, neural signalling), and iNOS (inducible, inflammatory). BPC-157 is notable for its interaction with all three NOS isoforms — upregulating eNOS (cardioprotective NO), modulating nNOS (relevant to nerve recovery), and differentially modulating iNOS depending on context. This NO system interaction is central to BPC-157’s vascular, neurological, and gastrointestinal effects.

Blood-Brain Barrier Penetrance

CNS-acting peptides face the challenge of crossing the blood-brain barrier (BBB) — a selective barrier formed by tight junctions between brain endothelial cells. Most peptides do not readily cross the BBB due to their hydrophilicity and size. Strategies to overcome this include:

Intranasal delivery — exploiting direct olfactory nerve transport from the nasal mucosa to the olfactory bulb and CNS, bypassing the BBB entirely. Selank and Semax are most commonly studied via intranasal route in Russian clinical research.

Structural modification — designing peptides with lipophilic modifications or reduced hydrogen bond donors to improve passive BBB penetrance.

Peripheral targets with CNS effects — several peptides (MOTS-C, DSIP) may achieve CNS effects indirectly through peripheral hormonal or neural signalling rather than direct CNS penetrance.

Summary: Mechanism Diversity in Research Peptides

Research peptides achieve their effects through a broad toolkit of mechanisms: GPCR activation (secretagogues, PT-141), RTK transactivation (GHK-Cu, IGF-1 variants), intracellular actin regulation (TB-500), neurotrophic factor upregulation (Selank, Semax), angiogenesis promotion (BPC-157, GHK-Cu, TB-500), HPA axis modulation (DSIP, Selank, Epitalon), and immunomodulation (Thymosin Alpha-1, LL-37, Selank). Understanding which mechanism is relevant to a given research question is the foundation of rational peptide compound selection for UK researchers.